The first six weeks: protecting the scaffold

Leaving the clinic after a ChondroFiller injection, the most immediate question is a practical one: what is safe to do right now, and what should be avoided? The first four to six weeks are designated the Protect phase — a period in which joint loading is kept to a minimum while controlled, guided movement is actively encouraged from the outset to prevent stiffness.

The rationale sits in the biology of the scaffold itself. ChondroFiller liquid is an injectable Type I collagen scaffold that gels within three to five minutes of injection, bonding directly to fibrin already present in the joint environment. Over the days and weeks that follow, the patient's own progenitor cells begin migrating into this matrix — a process known as acellular matrix-induced chondrogenesis. Until the scaffold has stabilised sufficiently to withstand mechanical load, premature stress risks disrupting that early cell migration. The phasing is not over-caution; it reflects what the biology requires at each stage.

Patients are not immobilised during this window. Gentle, purposeful movement forms part of the plan from the beginning — the aim is to preserve joint mobility while protecting the scaffold from compressive or shear forces it is not yet ready to bear. The specific weight-bearing level and any activity restrictions are set by the treating clinician according to which joint has been treated, the size and location of the defect, and the patient's overall presentation. There is no single protocol that applies uniformly across all joints.

What happens at your six-week review

The six-week review is included as standard in the London Cartilage Clinic's ChondroFiller injection package — part of the same package that covers the initial consultation, ultrasound, and IV antibiotic cover. Its timing has a specific clinical logic.

Six weeks marks the approximate close of the Protect phase: the period during which the collagen scaffold has been stabilising and the patient's own progenitor cells migrating into the matrix. Before physiotherapy can progress to the Strengthen phase — supervised muscle work and the introduction of low-impact cardiovascular activity — the treating clinician needs to confirm the joint is ready to take on that increased load.

The appointment focuses on scaffold stability and any residual swelling or inflammation. What is examined and how individual findings are weighted is determined by clinical assessment on the day; there is no single checklist that maps uniformly across every joint type or defect pattern, and the variety of joints ChondroFiller can treat makes a one-size approach impractical.

Where imaging is warranted, a post-injection MRI may be arranged at or following this review. In patients after ChondroFiller injection, imaging has shown reduction in bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space — structural changes that reflect scaffold integration rather than symptom relief alone. Individual scan results vary.

Outcome measures — NRS pain scores, IKDC scores for knee patients, and DASH disability scores for hand and wrist patients — provide objective reference points at this stage and at later reviews. Tracking these from the pre-injection baseline gives both clinician and patient a clear picture of how the joint is progressing over the months that follow.

When physiotherapy begins in earnest

Once the six-week review has confirmed the scaffold is stable and the joint ready to progress, supervised physiotherapy shifts into a higher gear. The Strengthen phase — broadly weeks six to twelve — has two primary targets: rebuilding the muscle strength and joint stability that typically deteriorate during the initial rest period, and reintroducing cardiovascular conditioning without placing undue stress on the still-maturing scaffold.

In practice, this means a combination of controlled resistance and stability work directed at the muscles surrounding the treated joint, alongside low-impact aerobic activity. Stationary cycling and swimming are typically the first cardiovascular options introduced, because both avoid the compressive or impact forces that higher-load activities impose. The progression is deliberate — the scaffold continues to develop during this window, and loading it too aggressively too soon risks compromising the repair process that has been under way since the injection.

There is no single named exercise protocol that is standard across all ChondroFiller patients. The research and clinical guidance in this area is principle-based rather than prescriptive: the physiotherapist tailors the programme to the individual's joint, defect pattern, baseline fitness, and response as the weeks progress. Physiotherapy at this stage is not an optional add-on — the quality of the rehabilitation directly influences the outcome.

Patients are advised to seek a physiotherapist with experience in cartilage rehabilitation; the London Cartilage Clinic team can provide guidance on appropriate referral where needed.

Progressing to functional loading (months 2–6)

Around month two, the focus shifts from building a stable base to functional loading — the phase when rehabilitation starts to resemble the activities patients actually want to return to.

Jogging is typically the first higher-demand activity introduced, progressing to lateral movement and sport-specific conditioning drills as the joint tolerates them. Impact activities and rotational loading come last, not first — the sequence matters because each step tests the scaffold's integration under progressively greater mechanical demand. All progression remains under physiotherapist supervision; self-directed escalation is not recommended.

How quickly any individual moves through this phase is guided by how the joint responds — tracked through pain scores on the NRS and functional measures such as the IKDC — rather than by the calendar alone. A joint that is still producing significant effusion or reporting disproportionate pain after a session warrants a slower pace, irrespective of where the patient is in the timeline.

For broader context, research into comparable surgical bioscaffolds in athletic populations offers a useful bracket. Studies of Hyalofast — a hyaluronate-based scaffold delivered surgically — found that professional athletes undertaking early full load-bearing rehabilitation returned to pre-injury sport level in approximately 2.5 to 3 months. These figures come from surgical scaffold procedures in trained athletes and do not map directly to ChondroFiller injection; they indicate what is biologically possible under optimal conditions rather than setting a standard expectation for all patients.

For most people, a gradual return to full sport and high-impact activity typically falls within months six to twelve.

Getting back to sport and full activity

The return to sport window between months six and twelve is when the numbers patients track during physiotherapy start to translate into something tangible.

Published evidence documents significant reductions in both NRS pain scores and DASH disability scores over this period, alongside marked improvements in grip and pincer strength for patients treated in upper-limb joints. Together these measures capture something that a single score cannot: the difference between a joint that can be managed and one that can be used.

The IKDC improvement of approximately 30 points at twelve months — roughly the distance between significant activity limitation and near-normal function — is consistent with that picture. What explains the continued trajectory is the scaffold's natural life cycle: the collagen matrix is progressively resorbed over one to two years and replaced by the patient's own repair tissue. Recovery does not plateau at the injection date; structural and functional improvement continue along a longer arc.

How quickly any individual reaches their ceiling depends on factors the calendar cannot fully capture — defect size, the joint involved, age, and sustained adherence to the physiotherapy programme across the full recovery period. For small joints, consolidation may be largely complete within weeks; for larger load-bearing joints, the two-year window is the more realistic frame. What the evidence consistently shows is that for patients who commit to rehabilitation, the gains are real, measurable, and durable.

Recovery in small joints — and taking the next step

Small joints behave differently under load, and that biological reality compresses the recovery timeline considerably. In the hand, wrist, foot, and thumb, the protect window that stretches to six weeks in larger joints often closes in one to two — not because the scaffold works faster, but because smaller joints carry different mechanical demands and defect volumes are typically more limited. The phased logic remains the same; the timescales simply collapse.

That distinction matters across the full range of joints in which ChondroFiller injection is used: knee, hip, ankle, shoulder, elbow, wrist, and small hand joints. A patient managing a thumb basal joint defect and one addressing a femoral condyle lesion share the same scaffold biology and the same rehabilitation principles, but their practical timelines diverge from the first week onward. Recovery expectations need to be calibrated to the specific joint, not borrowed from a general figure.

An assessment at the London Cartilage Clinic on Harley Street — where ChondroFiller injection is delivered in the UK — is the point at which those specifics can be established: defect size, joint location, mechanical loading demands, and what a realistic individual recovery arc looks like. For most load-bearing joints, that arc is measured in months. For smaller peripheral joints, weeks is often the more accurate frame.

1. [1] Hyalofast Cartilage Repair Surgery with a Full Load-Bearing Rehabilitation Program One Day after Operation Reduces the Time for Professional Athletes to Return to Play. (2023). https://doi.org/10.3390/medicina59040804 https://doi.org/10.3390/medicina59040804
2. [2] Articular Cartilage Reconstruction with Hyaluronate-Based Scaffold Significantly Decreases Pain and Improves Patient's Functioning. (2023). https://doi.org/10.3390/jcm12237342 https://doi.org/10.3390/jcm12237342